NCT02811159 2019-06-27
An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Terminated
Clinical Trials
10 trialsNCT02323646 2019-06-25
Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT02301897 2019-06-19
A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT00958334 2019-06-18
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
Repros Therapeutics Inc.
Phase 2 Completed
NCT01451424 2014-08-29
Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT00958893 2014-08-25
An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext
Repros Therapeutics Inc.
Phase 2 Terminated
NCT00683917 2014-08-21
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Terminated
NCT00882258 2014-07-08
Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT01631903 2014-04-16
Extension of Study ZPV-200
Repros Therapeutics Inc.
Phase 2 Completed
NCT01739621 2014-04-16
Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200
Repros Therapeutics Inc.
Phase 2 Completed